Table 4. Clinical outcomes in exon 20 insertion treated with TKI.
| Article reference | Research type | N, cases in the study | TKI therapy | ORR (%) | DCR (%) | Median PFS (month) | Median OS (month) |
|---|---|---|---|---|---|---|---|
| Yang, 2015 (2) | Prospective | 23 | 2nd | 9% | 65% | 2.7 (1.8–4.2) | 9.2 (4.1–14.2) |
| Wu, 2011 (24) | Retrospective | 11 | 1st | 0.00% | NR | 1.4 | 4.8 |
| Xu, 2016 (16) | Retrospective | 12 | 1st | 8.30% | 58.30% | 2.0 (0–5.41) | 16.69 (13.93–19.45) |
| Kuiper, 2016 (36) | Retrospective | 16 | 1st | 0% | 56% | 2.9 (2.3–3.6) | 9.7 (0–21.1) |
| Chen, 2017 (41) | Retrospective | 9 | 1st | 11.10% | 77.80% | 3.1 (1.6–4.6) | 6.1 (4.4–27.8) |
| Tu, 2017 (52) | Retrospective | 12 | 1st | 0% | NR | 3.0 (1.3–4.7) | 12.5 (0–25.5) |
NR, not reported; NE, not estimable; TKI, tyrosine kinase inhibitor; PFS, progression-free survival; ORR, objective response rate; DCR, disease control rate.